CanBas Co (TSE:4575) Research & Development: 円762.27 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4575 CanBas Co Ltd TSE:4575
31 GF Score
Price 円796.00
View Full Analysis

What is CanBas Co Research & Development?

CanBas Co TSE:4575 +5.99% 31 Research & Development is 円762.27 Mil as of Dec. 2025. GuruFocus rates TSE:4575 with a GF Score™ of 31/100.

Research & Development is the aggregate amount of research and development expenses during the year. CanBas Co's Research & Development for the three months ended in Dec. 2025 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was 円762.27 Mil.

CanBas Co  (TSE:4575) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CanBas Co Research & Development Related Terms

CanBas Co Research & Development Historical Data

* Premium members only.

The historical data trend for CanBas Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanBas Co Research & Development Chart

CanBas Co Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 430.24 607.78 671.04 983.49 820.00

CanBas Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 258.70 238.43 282.62 0.00 241.22
TSE:4575
31GF Score
CanBas Co Ltd TSE:4575
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanBas Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円762.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円762.27 Mil mean?
CanBas Co (TSE:4575) has a Research & Development of 円762.27 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on CanBas Co and its competitors.
Is CanBas Co's Research & Development too high?
CanBas Co's current Research & Development is 円762.27 Mil. Overall, CanBas Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CanBas Co's Research & Development compare to VRTX and REGN?
CanBas Co's Research & Development of 円762.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CanBas Co and its competitors. CanBas Co's current Research & Development is 円762.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanBas Co stock overvalued right now?
CanBas Co (TSE:4575) has a current Research & Development of 円762.27 Mil. The current Research & Development is 円762.27 Mil. CanBas Co's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CanBas Co (TSE:4575), the current Research & Development is 円762.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CanBas Co Business Description

Address 2-2-1 Otemachi, Numazu, Shizuoka, JPN, 410-0891
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
31GF Score

Get the complete analysis for TSE:4575

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円796.00
Price